Railpen, the pension manager overseeing more than £34 billion for UK railway pension schemes, has returned with a revised takeover proposal for IP Group after the science and technology investment firm rejected its initial approach last month. The new offer, announced today, raises the cash component to 61p per share from 59p and adds two additional sweeteners: IP Group's entire stake in Oxford Nanopore Technologies and a potential payout linked to the value of IP Group's holding in clinical-stage biotech company Metsera by the end of 2029.
What's in the Sweetened Offer?
Under the revised terms, Railpen is offering 61p per share in cash for each IP Group share it does not already own. Railpen currently holds an 18.4% stake in IP Group, making it the company's largest shareholder. The cash component alone represents a modest increase from the 59p per share offered in the initial bid, which IP Group's board rejected as undervaluing the company.
In addition to the cash, Railpen is proposing to distribute IP Group's entire holding in Oxford Nanopore Technologies to IP Group shareholders. Railpen values this stake at 10.6p per IP Group share. Oxford Nanopore is a publicly traded company that develops DNA and RNA sequencing technology, and IP Group has been a long-term investor in the firm.
The third component is a contingent value right (CVR) tied to any increase in the value of IP Group's stake in Metsera, a clinical-stage biotech company, by the end of 2029. Railpen estimates this CVR could be worth up to 11.3p per IP Group share, though the actual payout depends on Metsera's performance and any future liquidity events, such as an IPO or acquisition.
Why Railpen Is Pursuing IP Group
IP Group is a UK-based intellectual property commercialisation firm that invests in early-stage science and technology companies, particularly in the life sciences, cleantech, and deep tech sectors. The company has a portfolio that includes stakes in Oxford Nanopore, Metsera, and numerous other startups. Railpen's interest likely stems from IP Group's exposure to high-growth areas like genomics and biotechnology, which align with long-term trends in healthcare and technology.
For Railpen, acquiring IP Group would provide direct control over a diversified portfolio of science-based investments, potentially offering higher returns than simply holding shares in the company. The pension manager has been increasing its stake in IP Group over the past year, and a full takeover would consolidate its position.
IP Group's board rejected the initial 59p offer, arguing that it did not reflect the full value of the company's portfolio, particularly the potential upside from its holdings in Oxford Nanopore and Metsera. The new offer attempts to address that concern by including those stakes directly in the deal.
What It Means for Investors
For current IP Group shareholders, the revised offer presents a mix of immediate cash and potential future value. The 61p cash component provides a floor, while the Oxford Nanopore stake offers a liquid asset that can be sold or held. The Metsera CVR is more speculative, as its value depends on the biotech company's success over the next five years.
Investors should note that the offer is still subject to IP Group's board approval and regulatory clearance. If the board continues to view the bid as inadequate, Railpen may need to raise its offer further or walk away. The outcome will depend on how both sides value IP Group's portfolio, especially the less liquid stakes in private companies.
For everyday investors, this deal highlights the growing trend of pension funds and institutional investors seeking direct exposure to venture capital and science-based investments. While such deals can offer higher returns, they also carry higher risk and longer time horizons. Investors in IP Group should watch for any competing bids or further negotiations, as the final price could change.
Broader Market Context
The bid comes amid a period of heightened M&A activity in the UK small-cap and mid-cap space, as institutional investors look to take advantage of relatively low valuations. IP Group's shares have traded below net asset value for some time, making it an attractive target for a buyer like Railpen that can unlock value through direct ownership.
In related news, EQT recently raised its bid for Kakaku.com in a Japanese buyout battle, showing that pension funds and private equity firms are increasingly willing to sweeten offers to win deals. Similarly, AMP shares surged on an upgraded profit forecast, reflecting broader optimism in financial services.
Investors should also keep an eye on the tech and biotech sectors, as Netflix's recent warning about slower growth and retreats in AI chip stocks suggest that market sentiment can shift quickly. For IP Group, the outcome of this bid will depend on how the market values its portfolio in the coming weeks.
What's Next
IP Group's board is expected to review the revised offer and respond within the next few weeks. If accepted, the deal would likely close by mid-2025, subject to shareholder and regulatory approvals. If rejected, Railpen may either raise its bid again or walk away, potentially sending IP Group's shares lower.
For now, IP Group shareholders have a clear choice: accept the cash and stakes on offer, or hold out for a better deal. The coming days will reveal whether Railpen's sweetened bid is enough to win over the board.
